Guangdong Zhenjiankang Medical Technology Development Co., Ltd. has passed the Hong Kong Stock Exchange Main Board listing hearing under Chapter 18A, marking a key step towards a potential public listing.

• Commercial Growth: Revenue increased from RMB 1.791 million in 2024 to RMB 12.178 million in 2025, supported by the delivery of six surgical robotic systems.
• Market Position: The company delivered six percutaneous puncture surgical robot systems in 2025, representing a 36.4% share of the domestic market, according to CIC Consulting.
• International Expansion: The company plans to submit its European CE Mark application in January 2026 and expects to obtain certification in the fourth quarter of 2026.

This summary is based on an article published by Zhitong Finance via Moomoo.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.